Please login to the form below

Not currently logged in
Email:
Password:

Baiyunshan and Baxter finalise parenteral nutrition jv

Baxter International and Guangzhou Baiyunshan Pharmaceutical establish a joint venture to produce and sell parenteral nutrition products in China

Baxter International and Guangzhou Baiyunshan Pharmaceutical (GBP) have formally established a joint venture (jv) to produce and sell parenteral nutrition products in China

The jv will operate as Guangzhou Baxter Qiaoguang Healthcare (GBQH) and will be based in Guangzhou province. Per the November 2006 agreement, both companies have entered a 50/50 jv and are each investing between USD 65m and USD 70m.

GBP has contributed its existing parenteral nutrition manufacturing facility located in Guangzhou, while Baxter is providing new product technologies, technical expertise, product line management and clinical and marketing support.

Parenteral nutrition products are administered intravenously to provide life-sustaining support for patients who cannot achieve adequate nutrition through other means. The new jv will manufacture and sell current Baiyunshan parenteral nutrition offerings along with Baxter's nutrition products.

Baxter's ClinOleic, an olive oil-based parenteral emulsion, and Clinimix, a dual-chamber bag parenteral solution are currently produced in Belgium. Baiyunshan's parenteral products will continue to be produced at the Guangzhou facility, which will gradually expand to include the production of Baxter's products.

Baxter's FY06 sales in China totalled USD 150m and have increased approximately 25 per cent per year since 2004.

8th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics